Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Willowood Chemicals Limited is currently focused on the Biotechnology & Pharmaceuticals technology area, where it has 1 pending office action. This action is being processed within 1 distinct art unit, indicating a concentrated technical scope for the company's current filings. The involvement of 1 distinct examiner, HAGOPIAN, CASEY SHEA, means that the company's immediate prosecution path is managed by a single individual. This 1 busiest examiner pending office action represents the entirety of the company's active workload at the patent office.
For a practitioner, the concentration of 1 pending office action under 1 distinct examiner in 1 distinct art unit requires a highly specific strategy. The outcome of the company's current efforts in the Biotechnology & Pharmaceuticals sector depends entirely on the review by HAGOPIAN, CASEY SHEA. While this ratio of actions to examiners simplifies the administrative tracking of the portfolio, it also focuses all prosecution risk on a single point of review. The reliance on 1 distinct art unit suggests that Willowood Chemicals Limited is pursuing a very specific technical objective within its current patent application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGOPIAN, CASEY SHEA | 1 | 54.4% | +33.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278536 | Insecticidal Composition Comprising of Diamide, Moulting Hormone Agonist and Pyrethroid | HAGOPIAN, CASEY SHEA | 6d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18278536 | Insecticidal Composition Comprising of Diamide, Moulting Hormone Agonist and Pyrethroid | HAGOPIAN, CASEY SHEA | 1617 | §103 | Final Rejection | 6d | Pending | Aug 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial